Table 2.

Specificity and activity of tumor antigen-reactive TIL used for adoptive cell therapy


Patient no.

T2

T2/irrelevant peptide, 1 μM

T2/MART-1, 1 μM

T2/MART-1, 10 μM

888mel (A2 MART-1+)

526mel (A2+ MART-1+)

624mel (A2+ MART-1+)

2098mel (A2+ MART-1)

VβTCR of antigen-reactive clones
9   59   92   5216  ND   5   4898  4794  ND   Vβ12  
10   10   36*  ND   595  12   5580  4125  ND   Vβ7  
20   2   5   1165  2516  20   2061  1011  76   ND  
21   30   17   15   19   12   25   21   1598  Vβ22  
23   23   22   1360  3040  17   1292  399  53   Vβ14  
28
 
3
 
7
 
2517
 
2872
 
20
 
2061
 
2148
 
167
 
Vβ16
 

Patient no.

T2

T2/irrelevant peptide, 1 μM

T2/MART-1, 1 μM

T2/MART-1, 10 μM

888mel (A2 MART-1+)

526mel (A2+ MART-1+)

624mel (A2+ MART-1+)

2098mel (A2+ MART-1)

VβTCR of antigen-reactive clones
9   59   92   5216  ND   5   4898  4794  ND   Vβ12  
10   10   36*  ND   595  12   5580  4125  ND   Vβ7  
20   2   5   1165  2516  20   2061  1011  76   ND  
21   30   17   15   19   12   25   21   1598  Vβ22  
23   23   22   1360  3040  17   1292  399  53   Vβ14  
28
 
3
 
7
 
2517
 
2872
 
20
 
2061
 
2148
 
167
 
Vβ16
 

Interferon-gamma secretion (pg/mL) from patient TIL stimulated with T2 cells pulsed with peptide at the indicated concentrations or with melanoma cell lines. Cytokine secretion from TIL was measured in multiple independent assays. Cryopreserved TIL were thawed and rested overnight in CM and rhIL-2 (50 cU/mL) prior to establishment of cocultures. T2 cells were pulsed with either MART-1:27-35 peptide or irrelevant peptide, gp 100:209-27.

ND indicates not determined; Vβ TCR, specific tumor antigen-reactive T-cell clones identified in TIL that persisted in the peripheral blood after adoptive transfer to lymphodepleted patients.

*

Control gp 100:280-288 peptide was used.

Values represent specific cytokine secretion specified as more than 3-fold increase compared with controls and more than 100 pg/mL concentration.